Consort Completes Acquisition of Aesica Holdco Ltd

Consort has completed the acquisition of Aesica Holdco Ltd.

The board considers that the acquisition represents an excellent opportunity for Consort and is directly in line with Consort's articulated strategy of diversifying into adjacent markets and technologies to capture additional value in the drug/device supply chain.

Aesica is one of Europe's leading pharmaceutical contract development and manufacturing organisations (CDMO), providing contract development and manufacturing services for finished dose and APIs to the global pharmaceutical industry. Since the Aesica business was established in 2004, it has grown both organically and through acquisitions and has established key strategic relationships with major global blue-chip pharmaceutical companies.

Jon Glenn, Consort's CEO, said: "We are excited by the acquisition of Aesica which represents a very strong fit with our existing strategy of diversifying into adjacent markets and technologies to capture additional value in the drug/device supply chain. As one of Europe's leading pharmaceutical CDMOs, Aesica is highly complementary to Bespak's existing business and provides a number of clear strategic, competitive and value-enhancing benefits for the Enlarged Group."

 Dr Robert Hardy, Chief Executive, Aesica said: “We are proud of what we have accomplished over the last decade, developing Aesica through a combination of organic growth, continuous process improvement and investment.  We continue to see many exciting opportunities in the pharmaceutical contract manufacturing sector and we look forward to pursuing these under the ownership of Consort Medical. Our position as a pharmaceutical CDMO is now further strengthened in the global market place through the alignment Aesica has with Bespak, as part of the enlarged Consort Medical group. With our collective strengths we will continue to provide high quality pharmaceutical contract development and manufacturing services internationally." 

Capitalised terms not defined herein, are defined at Part XVIII of the combined shareholder prospectus and circular published by the Company on 30 September 2014.